Patients displaying a non-classified, severe and resistant inflammatory disease
Conditions
Brief summary
Response will be assessed at month 6 after treatment initiation with a composite endpoint defined as improvement of at least 2 of the 3 following parameters: - 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10), - and/or 50% improvement of cutaneous activity assessed by the involved skin surface area, - and/or 50% decrease or nomalisation of biological markers of inflammation (either CRP, ESR or fibrin)
Interventions
DRUGTOCILIZUMAB
DRUGSECUKINUMAB
DRUGANAKINRA
DRUGADALIMUMAB
DRUGRITUXIMAB
DRUGUSTEKINUMAB
Sponsors
Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response will be assessed at month 6 after treatment initiation with a composite endpoint defined as improvement of at least 2 of the 3 following parameters: - 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10), - and/or 50% improvement of cutaneous activity assessed by the involved skin surface area, - and/or 50% decrease or nomalisation of biological markers of inflammation (either CRP, ESR or fibrin) | — |
Countries
France
Outcome results
None listed